Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus weekly paclitaxel versus weekly paclitaxel in relapsed ovarian sex-cord stromal tumors
2012-002841-39Phase 2Completed
- Sponsor
- Arcagy-Gineco
- Start
- Jun 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and paclitaxel in Ovarian sex-cord stromal tumor (SCST) (2 arms), sponsored by Arcagy-Gineco. Primary endpoint: 6-month non-progression rate. Started Jun 2013; status: completed.
02
Drugs
bevacizumabpaclitaxel
03
Conditions
Ovarian sex-cord stromal tumor (SCST)
Beyond the preview
Go deeper on 2012-002841-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002841-39.